Annals of Oncology 8:163-168, 1997
© 1997 European Society for Medical Oncology
research-article |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
1Departments of Oncology Stockholm
2Departments of Surgery Stockholm
3Departments of Centre for Caring Sciences, University of Uppsala Uppsala, Stockholm
4Departments of Oncology, Huddinge, University Hospital Stockholm
5Departments of Surgery Swedan
6Departments of Oncology Centralsjukhuset, Karlstad, Sweden
7Departments of Surgery Sjukhuset, Säffle, Sweden
8Departments of Surgery Lasarettet, Mota, Sweden
Correspondence to: Bengt Glimelius, MD Department of Oncology University of Uppsala S-751 85 Uppsala Sweden
BACKGROUND:: The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality. The aim of this study was to estimate any gain in the quantity and quality of life produced by chemotherapy in these patients.
PATIENTS AND METHODS:: Between January 1991 and February 1995, 61 patients with gastric cancer were randomized to either chemotherapy in addition to best supportive care or to best supportive care. Chemotherapy was allowed in the latter group if the supportive measures did not lead to palliation. Chemotherapy was the ELF-regimen consisting of 5-fluorouracil, leucovorin and etoposide, or, in elderly patients with poor performance, a 5-fluorouracil/leucovorin regimen (FLv). Quality of life was evaluated with the EORTC-QLQ-C30 instrument.
RESULTS:: More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05). A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01). Overall survival was longer in the chemotherapy group (median 8 vs. 5 months) although the difference was not statistically significant (P = 0.12). After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003). Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).
CONCLUSIONS:: The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer. The number of patients who benefit from treatment is, however, still rather limited.
chemotherapy, gastric cancer, palliation, randomized study
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. I. Cherny, A. P. Abernethy, F. Strasser, R. Sapir, D. Currow, and S. Y. Zafar Improving the Methodologic and Ethical Validity of Best Supportive Care Studies in Oncology: Lessons From a Systematic Review J. Clin. Oncol., November 10, 2009; 27(32): 5476 - 5486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. TSUTANI, M. OHARA, T. SUZUKI, K. MINAMI, E. MIYAHARA, A. KAMEDA, and Y. NOSO Docetaxel and S-1 as a First-line Treatment in Patients with Advanced or Recurrent Gastric Cancer Anticancer Res, July 1, 2009; 29(7): 2775 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, and D. Wang Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer Jpn. J. Clin. Oncol., April 1, 2009; 39(4): 237 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. M. Seol, M. K. Song, Y. J. Choi, G. H. Kim, H. J. Shin, G. A. Song, J. S. Chung, and G. J. Cho Oral Fluoropyrimidines (Capecitabine or S-1) and Cisplatin as First Line Treatment in Elderly Patients with Advanced Gastric Cancer: A Retrospective Study Jpn. J. Clin. Oncol., January 1, 2009; 39(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-E. Al-Batran, J. T. Hartmann, R. Hofheinz, N. Homann, V. Rethwisch, S. Probst, J. Stoehlmacher, M. R. Clemens, R. Mahlberg, M. Fritz, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Ann. Onc., November 1, 2008; 19(11): 1882 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-D. Seo, K.-W. Lee, J. H. Lim, H. G. Yi, D.-Y. Kim, D.-Y. Oh, J. H. Kim, S.-A. Im, T.-Y. Kim, J. S. Lee, et al. Irinotecan Combined with 5-Fluorouracil and Leucovorin as Second-line Chemotherapy for Metastatic or Relapsed Gastric Cancer Jpn. J. Clin. Oncol., September 1, 2008; 38(9): 589 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Aykan and E. Idelevich The role of UFT in advanced gastric cancer Ann. Onc., June 1, 2008; 19(6): 1045 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Park, E. Nam, J. Park, E. K. Cho, D. B. Shin, J. H. Lee, W. K. Lee, M. Chung, and S. I. Lee Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer Ann. Onc., April 1, 2008; 19(4): 729 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-E. Al-Batran, J. T. Hartmann, S. Probst, H. Schmalenberg, S. Hollerbach, R. Hofheinz, V. Rethwisch, G. Seipelt, N. Homann, G. Wilhelm, et al. Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie J. Clin. Oncol., March 20, 2008; 26(9): 1435 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takiuchi, M. Goto, H. Imamura, H. Furukawa, M. Imano, H. Imamoto, Y. Kimura, H. Ishida, K. Fujitani, H. Narahara, et al. Multi-Center Phase II Study for Combination Therapy with Paclitaxel/Doxifluridine to Treat Advanced/Recurrent Gastric Cancer Showing Resistance to S-1 (OGSG 0302) Jpn. J. Clin. Oncol., March 1, 2008; 38(3): 176 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, A. R. Norman, et al. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer N. Engl. J. Med., January 3, 2008; 358(1): 36 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hwang Resectable Esophageal, Gastroesophageal Junction, and Gastric Cancers: Therapy Is Distinct for Gastric Cancer ASCO Educational Book, January 1, 2008; 2008(1): 172 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Jo, J.-L. Lee, M.-H. Ryu, S. J. Sym, S. S. Lee, H. M. Chang, T. W. Kim, J. S. Lee, and Y.-K. Kang Docetaxel Monotherapy as a Second-line Treatment after Failure of Fluoropyrimidine and Platinum in Advanced Gastric Cancer: Experience of 154 Patients with Prognostic Factor Analysis Jpn. J. Clin. Oncol., December 1, 2007; 37(12): 936 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Kim, K. Yamaguchi, Y.-J. Bang, H. Takiuchi, W. K. Kang, A. Sato, Y.-K. Kang, J. Sakamoto, C. Abe, and Y. Sakata Phase II Study of Biweekly Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Gastric Cancer: Korea Japan Collaborative Study Group Trial Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym054v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ajani, V. M. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, A. Rodrigues, M. Fodor, Y. Chao, E. Voznyi, et al. Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group J. Clin. Oncol., August 1, 2007; 25(22): 3205 - 3209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ajani, V. M. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, A. Rodrigues, M. Fodor, Y. Chao, E. Voznyi, et al. Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group J. Clin. Oncol., August 1, 2007; 25(22): 3210 - 3216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Lutz, H. Wilke, D.J. T. Wagener, U. Vanhoefer, K. Jeziorski, S. Hegewisch-Becker, L. Balleisen, E. Joossens, R. L. Jansen, M. Debois, et al. Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie J. Clin. Oncol., June 20, 2007; 25(18): 2580 - 2585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-C. Jeung, S. Y. Rha, H. K. Kim, H. Y. Lim, S. Kim, S. Y. Kim, S. J. Gong, C. H. Park, J. B. Ahn, S. H. Noh, et al. Multi-Institutional Phase II Study of S-1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations Oncologist, May 1, 2007; 12(5): 543 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Lee, J.-L. Lee, M.-H. Ryu, H. M. Chang, T. W. Kim, H.-J. Kang, W. K. Kim, J. S. Lee, and Y.-K. Kang Combination Chemotherapy with Capecitabine (X) and Cisplatin (P) as First Line Treatment in Advanced Gastric Cancer: Experience of 223 Patients with Prognostic Factor Analysis Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 30 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Van Cutsem, V. M. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, A. Rodrigues, M. Fodor, Y. Chao, E. Voznyi, et al. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group J. Clin. Oncol., November 1, 2006; 24(31): 4991 - 4997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W Ichikawa and Y Sasaki Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients Ann. Onc., November 1, 2006; 17(11): 1665 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Orditura, E Martinelli, G Galizia, C Carlomagno, G Aurilio, L Vecchione, E. Lieto, S De Placido, G Catalano, F Ciardiello, et al. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study Ann. Onc., October 1, 2006; 17(10): 1529 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Giordano, A. Jatoi, P. J. Stella, N. Foster, L. K. Tschetter, S. R. Alberts, S. R. Dakhil, J. A. Mailliard, P. J. Flynn, and D. A. Nikcevich Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group Ann. Onc., April 1, 2006; 17(4): 652 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kim, J.-H. Park, S.-J. Bang, D.-H. Kim, H. R. Cho, G. Y. Kim, and Y. J. Min A Phase II Study of Docetaxel and Cisplatin in Patients with Gastric Cancer Recurring After or Progressing During 5-FU/Platinum Treatment Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 727 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-W. Lee, S.-A. Im, T. Yun, E. K. Song, I. i. Na, H. Shin, I. S. Choi, D.-Y. Oh, J. H. Kim, D.-W. Kim, et al. Phase II Trial of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Gastric Cancer Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 720 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ajani Evolving Chemotherapy for Advanced Gastric Cancer Oncologist, October 1, 2005; 10(suppl_3): 49 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takiuchi, H. Narahara, T. Tsujinaka, M. Gotoh, S.-i. Kawabe, K.-i. Katsu, H. Iishi, M. Tatsuta, K. Fujitani, H. Furukawa, et al. Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Gastric Cancer (OGSG 0002) Jpn. J. Clin. Oncol., September 1, 2005; 35(9): 520 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ajani, M. B. Fodor, S. A. Tjulandin, V. M. Moiseyenko, Y. Chao, S. C. Filho, A. Majlis, S. Assadourian, and E. Van Cutsem Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma J. Clin. Oncol., August 20, 2005; 23(24): 5660 - 5667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-Y. Oh, T.-Y. Kim, J. H. Kwon, J.-J. Lee, Y. Joh, D.-W. Kim, T.-Y. Kim, D. S. Heo, Y.-J. Bang, and N. K. Kim Docetaxel + 5-Fluorouracil + Cisplatin 3-day Combination Chemotherapy as a First-line Treatment in Patients with Unresectable Gastric Cancer Jpn. J. Clin. Oncol., July 1, 2005; 35(7): 380 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pozzo, C. Barone, J. Szanto, E. Padi, C. Peschel, J. Bukki, V. Gorbunova, V. Valvere, J. Zaluski, M. Biakhov, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study Ann. Onc., December 1, 2004; 15(12): 1773 - 1781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Bouche, J. L. Raoul, F. Bonnetain, M. Giovannini, P. L. Etienne, G. Lledo, D. Arsene, J. F. Paitel, V. Guerin-Meyer, E. Mitry, et al. Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803 J. Clin. Oncol., November 1, 2004; 22(21): 4319 - 4328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Wohrer, M. Raderer, and M. Hejna Palliative chemotherapy for advanced gastric cancer Ann. Onc., November 1, 2004; 15(11): 1585 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Souglakos, K. Syrigos, A. Potamianou, A. Polyzos, I. Boukovinas, N. Androulakis, Ch. Kouroussis, N. Vardakis, Ch. Christophilakis, A. Kotsakis, et al. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial Ann. Onc., August 1, 2004; 15(8): 1204 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Chau, A. R. Norman, D. Cunningham, J. S. Waters, J. Oates, and P. J. Ross Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer--Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data J. Clin. Oncol., June 15, 2004; 22(12): 2395 - 2403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Van Cutsem The Treatment of Advanced Gastric Cancer: New Findings on the Activity of the Taxanes Oncologist, June 2, 2004; 9(suppl_2): 9 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Shanafelt, C. Loprinzi, R. Marks, P. Novotny, and J. Sloan Are Chemotherapy Response Rates Related to Treatment-Induced Survival Prolongations in Patients With Advanced Cancer? J. Clin. Oncol., May 15, 2004; 22(10): 1966 - 1974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Mitry, J. Taieb, P. Artru, V. Boige, J.-N. Vaillant, M.-C. Clavero-Fabri, M. Ducreux, and P. Rougier Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma Ann. Onc., May 1, 2004; 15(5): 765 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-E. Al-Batran, A. Atmaca, S. Hegewisch-Becker, D. Jaeger, S. Hahnfeld, M. J Rummel, G. Seipelt, A. Rost, J. Orth, A. Knuth, et al. Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer J. Clin. Oncol., February 15, 2004; 22(4): 658 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Assersohn, G. Brown, D. Cunningham, C. Ward, J. Oates, J. S. Waters, M. E. Hill, and A. R. Norman Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma Ann. Onc., January 1, 2004; 15(1): 64 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Lamont and N. A. Christakis Complexities in Prognostication in Advanced Cancer: "To Help Them Live Their Lives the Way They Want to" JAMA, July 2, 2003; 290(1): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gill, A. Shah, N. Le, E. F. Cook, and E. M. Yoshida Asian Ethnicity-Related Differences in Gastric Cancer Presentation and Outcome Among Patients Treated at a Canadian Cancer Center J. Clin. Oncol., June 1, 2003; 21(11): 2070 - 2076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chvetzoff and I. F. Tannock Placebo Effects in Oncology J Natl Cancer Inst, January 1, 2003; 95(1): 19 - 29. [Abstract] [Full Text] [PDF]
|
|